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activity. Importantly, inhibition of NFkB with Bay 11-7085 (8.5 
mM) leads to loss of cell viability and is accompanied by decreased 
levels of HSP70 and HSP27, as well as their transcription factor, 
HSF-1, at the RNA and protein levels. Furthermore, overexpression 
of a phosphorylation-deficient mutant of IKBa in MIAPaCa-2 cells 
resulted in decreased NFkB activity and the loss of HSP70 expression.
Conclusion: HSP70 is known to be regulated by several mechanisms. 
Here we show a novel NFkB-mediated mechanism by which HSF-1 
and its transcriptional targets, HSP27 and HSP70 are down-regulated 
in pancreatic cancer cells in response to triptolide.
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Introduction: Although the oxidative stress and inflammation are 
closely related with breast cancer, there is no study directly examining 
the possible changes in vascular functions in the presence of breast 
carcinoma. The goal of the present study was to evaluate changes in 
vascular reactivity in tumor-bearing mice.
Patients (or Materials) and Methods: In this study, highly metastatic 
breast carcinoma cells which was derived from liver or brain metasta-
sis of 4T1 murine breast carcinoma (4TLM and 4TBM, respectively), 
and 67NR cells which is tumorogenic but nonmetastatic cells were 
used. Female Balb-c mice 8 to 10 weeks old were divided into fol-
lowing groups: (1) control; (2) injected with 67NR; (3) injected with 
4TLM; and (4) injected with 4TBM orthotopically. Thoracic aorta 
was removed 25 days after injection of tumor cells. Isometric tension 
studies were performed in response to potassium chloride (KCl), 
phenylephrine (Phe), acetylcholine (ACh, an endothelium-depend-
ent vasodilator), and sodium nitroprusside (SNP, an endothelium-
independent vasodilator). Endothelial nitric oxide synthase (eNOS), 
phosphorylated eNOS (Ser 1177) (p-eNOS), gp91phox, and tumor 
necrosis factor-α (TNF-α ) expressions in aortic tissues were demon-
strated by immunohistochemistry. The level of TNF-α in vascular 
tissue was evaluated by ELISA.
Results: Presence of tumor was resulted in significant inhibition of 
response to ACh in both 4TLM- and 4TBM-injected mice but not 
67NR-injected mice. Furthermore, both KCl and Phe-induced con-
traction of thoracic aorta was not changed significantly in tumor-
bearing animals. eNOS and p-eNOS expressions decreased while 
gp91phox and TNF-α expressions increased in endothelium sig-
nificantly in mice with metastatic breast carcinoma compared with 
67NR-injected and control mice. Moreover, TNF-α levels of thoracic 
aorta in 4TLM and 4TBM mice were higher than that of 67NR mice. 
Tumor-induced endothelial dysfunction determined by ACh-induced 
relaxation improved by superoxide dismutase (SOD), apocynin (a 
NADPH oxidase inhibitor), and infliximab (a TNF-α monoclonal 
antibody).
Conclusion: The findings of this study suggest that presence of 
metastatic breast carcinoma may cause a significant reduction in 
endothelium-dependent relaxation of thoracic aorta via NADPH 
oxidase-mediated oxidative stress and TNF-α production.
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Introduction: Cyclin D1 is required for cells to progress from the 
G1 phase of the cell cycle into the S phase. Mutation or overexpres-
sion of cyclin D1, often occurring in tumors, leads to uncontrolled 
cell cycle progression and proliferation. QTRRE (rodent) as well 
as ACHN and 786-O (human) cell models of renal cell carcinoma 
(RCC) display elevated cyclin D1 protein levels. Pentoxifylline (PTX), 
an FDA-approved competitive, nonspecific phosphodiesterase inhibi-
tor, has found recent use as an adjunct in chemotherapy for patients 
to help treat cachexia and capillary leak syndrome.
Patients (or Materials) and Methods: We utilized Western blot analy-
sis as well as propidium iodide-based cell cycle analysis to study the 
effects of PTX in our RCC cell models.
Results: Initially (0–8 hours), PTX induced a time- and dose- 
(35 µM–3.5 mM) dependent decrease in cyclin D1 levels in the RCC 
cell models. Cotreatment with PTX and the protein translation 
inhibitor, cycloheximide (5–25 µM), revealed a decrease in cyclin 
D1 protein half-life. Furthermore, the PTX-induced decrease of cyclin 
D1 was abolished in the presence of a proteasome inhibitor (MG-
132, 10 µM) in all 3 RCC cell models. Subsequently (12–72 hours), 
PTX caused maximal cyclin D1 decreases in QTRRE and ACHN 
cells, whereas cyclin D1 levels in 786-O cells recovered and surpassed 
initial amounts seen in the control. Concomitant with cyclin D1 lev-
els, QTRRE and ACHN cells demonstrated enhanced G1 phase cell 
cycle arrest at 24 hours (170% and 140%, respectively) compared 
with 786-O cells (107%) and the nontumorigenic human kidney cell 
line HK-2 (107%).
Conclusion: The data suggest that PTX decreases cyclin D1 protein 
levels by stimulating proteasomal degradation (and subsequent G1 
phase arrest), which is sustained in the QTRRE and ACHN but not 
786-O RCC cell models. The data reveal a need to better under-
stand the differences in PTX response between the RCC cell models. 
Moreover, an ability to predict a positive response to PTX may con-
tribute to better personalized cancer therapy treatment for patients. 
Because our findings also reveal a novel anticancer chemotherapeutic 
property of PTX, the utility of PTX as an adjuvant therapy in the 
treatment of cancer should be further explored.
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Introduction: Photodynamic therapy (PDT) is an anticancer treat-
ment that uses light to activate cytotoxic compounds killing cancer 
cells. Sonodynamic therapy (SDT) is a new anticancer treatment 
where ultrasound is used to trigger the cytotoxic effect of chemical 
compounds known as sonosensitizers. SDT is able to focus the ultra-
sound energy, generated by selected continuous or pulsed ultrasound 
such as shock waves (SW), onto malignant sites situated deeply inside 
tissues overcoming the main drawback linked to the use of PDT: the 
poor penetration of light in biological tissues. Even if the SDT mecha-
nism is still under debate, some researchers suggest a common basic 
